


AGI-5198

Cat. No.:	HY-18082		
CAS No.:	1355326-35-0		
Molecular Formula:	C ₂₇ H ₃₁ FN ₄ O ₂		
Molecular Weight:	462.56		
Target:	Isocitrate Dehydrogenase (IDH)		
Pathway:	Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMF : ≥ 50 mg/mL (108.09 mM)
 DMSO : 20.83 mg/mL (45.03 mM; Need ultrasonic)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent		Mass		
	Concentration		1 mg	5 mg	10 mg
	1 mM		2.1619 mL	10.8094 mL	21.6188 mL
	5 mM		0.4324 mL	2.1619 mL	4.3238 mL
	10 mM		0.2162 mL	1.0809 mL	2.1619 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: 2.08 mg/mL (4.50 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.08 mg/mL (4.50 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

AGI-5198 (IDH-C35) is a potent and selective mutant IDH1^{R132H} inhibitor with an IC₅₀ of 0.07 μM.

IC₅₀ & Target

IDH1

In Vitro

Measurements of R-2HG concentrations in pellets of TS603 glioma cells demonstrates dose-dependent inhibition of the

mutant IDH1 enzyme by AGI-5198. AGI-5198 does not impair colony formation of two patient-derived glioma lines that express only the wild-type IDH1 allele (TS676 and TS516)^[1]. Cancer cells heterozygous for the IDH1(R132H) mutation exhibits less IDH-mediated production of NADPH, such that after exposure to ionizing radiation (IR), there are higher levels of reactive oxygen species, DNA double-strand breaks, and cell death compared with IDH1 wild-type cells. These effects are reversed by the IDH1(R132H) inhibitor AGI-5198^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AGI-5198 (450 mg/kg, p.o.) causes 50 to 60% growth inhibition of the tumor growth from human glioma xenografts. Tumors from AGI-5198- treated mice show reduced staining with an antibody against the Ki-67 protein. AGI-5198 does not affect the growth of IDH1 wild-type glioma xenografts^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

PROTOCOL

Kinase Assay ^[1]

Inhibitory potency against the IDH2 R140Q and IDH2 R172K enzymes is determined in an endpoint assay in which the amount of NADPH remaining at the end of the reaction is measured by the addition of a large excess of diaphorase and resazurin. IDH2 R140Q is diluted to 0.25 µg/mL in 40 µL 1X Assay Buffer (150 mM NaCl, 50 mM potassium phosphate pH 7.5, 10 mM MgCl₂, 10% glycerol, 2 mM B-ME, 0.03% BSA) and incubated for 16 hours at 25°C in the presence of 1 µL of compound in DMSO. The reaction is started with the addition of 10 µL of Substrate Mix (20 µM NADPH, 8 µM alpha-ketoglutarate, in 1X Assay Buffer) and incubated for 1 hour at 25°C. Then, remaining NADPH is measured by the addition of 25 µL of Detection Mix (36 µg/mL diaphorase, 18 µM resazurin in 1X Assay buffer), incubated for 5 minutes at 25°C, and read as described above. IDH2 R172K is assayed as for IDH2 R140Q with the following modifications: 1.25 µg/mL of protein is used, the Substrate Mix contained 50 µM NADPH and 6.4 µM alpha-ketoglutarate, and the compound is incubated for 1 hour before starting the reaction.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay ^[1]

TS603 cells are grown in medium containing either AGI-5198 (1.5µM) or DMSO vehicle control. One week prior to harvest cells are transferred to differentiation medium (DMEM F12; 15 mM HEPES; 0.06% glucose; B27 without vitamin A; N2; Insulin/transferrin; 1% FBS) containing freshly added retinoic acid (1µM). ChIP of non-crosslinked cells is then carried out using established ChIP methods. 350 µg of lysate is immunoprecipitated-using anti-H3K9Me3, H3K27me3 or Rabbit Control IgG. After washing, ChIP DNA is eluted from protein G beads and analyzed by RT-PCR using SYBR green. Relative occupancy is calculated using the standard curve method and fold enrichment versus IgG. Enrichment in AGI- 5198-treated cells is normalized to vehicle control. Means and standard deviation are calculated from 4 technical replicates.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration ^[1]

SCID mice are injected subcutaneously with 10⁶ glioma cells, which are suspended in 100 µL of a 50:50 mixture of growth media and Matrigel. Once tumors have reached a measurable size, mice are randomized into the indicated treatment groups.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Clin Cancer Res. 2018 Apr 1;24(7):1705-1715.
- Cancer Res. 2018 Nov 15;78(22):6386-6398.
- Cancer Res. 2015 Nov 15;75(22):4790-802.
- J Med Chem. 2023 Mar 23.
- Cancer Metab. 2019 May 20;7:4.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Rohle D, et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. *Science*. 2013 May 3;340(6132):626-30.
- [2]. Molenaar RJ, et al. Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. *Cancer Res*. 2015 Nov 15;75(22):4790-802.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA